178 related articles for article (PubMed ID: 8142140)
1. Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development.
Scandella CJ; Kilpatrick J; Lidster W; Parker C; Moore JP; Moore GK; Mann KA; Brown P; Coates S; Chapman B
AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1233-44. PubMed ID: 8142140
[TBL] [Abstract][Full Text] [Related]
2. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
3. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
Steimer KS; Haigwood NL
Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
[TBL] [Abstract][Full Text] [Related]
4. Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies.
Jones DH; McBride BW; Roff MA; Farrar GH
Vaccine; 1995 Aug; 13(11):991-9. PubMed ID: 8525694
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters.
Azizi A; Anderson DE; Ghorbani M; Gee K; Diaz-Mitoma F
BMC Immunol; 2006 Oct; 7():25. PubMed ID: 17076905
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of V3-specific cleavage of recombinant HIV-1 gp120 produced in Chinese hamster ovary cells.
Du SX; Xu L; Viswanathan S; Whalen RG
Protein Expr Purif; 2008 Jun; 59(2):223-31. PubMed ID: 18406166
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.
Ditzel HJ; Binley JM; Moore JP; Sodroski J; Sullivan N; Sawyer LS; Hendry RM; Yang WP; Barbas CF; Burton DR
J Immunol; 1995 Jan; 154(2):893-906. PubMed ID: 7529290
[TBL] [Abstract][Full Text] [Related]
9. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.
Gorse GJ; Patel GB; Mandava M; Berman PW; Belshe RB
AIDS Res Hum Retroviruses; 1999 Jul; 15(10):921-30. PubMed ID: 10408729
[TBL] [Abstract][Full Text] [Related]
10. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
11. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.
Allaway GP; Ryder AM; Beaudry GA; Maddon PJ
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162
[TBL] [Abstract][Full Text] [Related]
12. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
[TBL] [Abstract][Full Text] [Related]
13. Antigenic variation in gp120s from molecular clones of HIV-1 LAI.
Moore JP; Yoshiyama H; Ho DD; Robinson JE; Sodroski J
AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1185-93. PubMed ID: 7511394
[TBL] [Abstract][Full Text] [Related]
14. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
15. Multiepitope polypeptide of the HIV-1 envelope induces neutralizing monoclonal antibodies against V3 loop.
Duarte CA; Montero M; Seralena A; Valdés R; Jiménez V; Benítez J; Narciandi E; Madrazo J; Padrón G; Sánchez G
AIDS Res Hum Retroviruses; 1994 Mar; 10(3):235-43. PubMed ID: 7517147
[TBL] [Abstract][Full Text] [Related]
16. Construction and characterization of a Salmonella typhi-based human immunodeficiency virus type 1 vector vaccine.
Fouts TR; Lewis GK; Hone DM
Vaccine; 1995 Apr; 13(6):561-9. PubMed ID: 7483777
[TBL] [Abstract][Full Text] [Related]
17. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
18. GP120: target for neutralizing HIV-1 antibodies.
Pantophlet R; Burton DR
Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
[TBL] [Abstract][Full Text] [Related]
19. The HIV-1 gp120 envelope protein has the intrinsic capacity to stimulate monokine secretion.
Clouse KA; Cosentino LM; Weih KA; Pyle SW; Robbins PB; Hochstein HD; Natarajan V; Farrar WL
J Immunol; 1991 Nov; 147(9):2892-901. PubMed ID: 1918997
[TBL] [Abstract][Full Text] [Related]
20. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
